Geron Corp
NASDAQ:GERN
Intrinsic Value
Geron Corp. operates as a biotechnology company. [ Read More ]
The intrinsic value of one GERN stock under the Base Case scenario is 10.708 USD. Compared to the current market price of 3.805 USD, Geron Corp is Undervalued by 64%.
Valuation Backtest
Geron Corp
Run backtest to discover the historical profit from buying and selling GERN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Geron Corp
Current Assets | 341.3m |
Cash & Short-Term Investments | 333.7m |
Receivables | 1.7m |
Other Current Assets | 6m |
Non-Current Assets | 52.7m |
Long-Term Investments | 43.3m |
PP&E | 4.7m |
Other Non-Current Assets | 4.7m |
Current Liabilities | 108.1m |
Accounts Payable | 6.2m |
Accrued Liabilities | 55m |
Other Current Liabilities | 46.9m |
Non-Current Liabilities | 38.1m |
Long-Term Debt | 35.1m |
Other Non-Current Liabilities | 3m |
Earnings Waterfall
Geron Corp
Revenue
|
237k
USD
|
Operating Expenses
|
-194.2m
USD
|
Operating Income
|
-193.9m
USD
|
Other Expenses
|
9.8m
USD
|
Net Income
|
-184.1m
USD
|
Free Cash Flow Analysis
Geron Corp
GERN Profitability Score
Profitability Due Diligence
Geron Corp's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Geron Corp's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
GERN Solvency Score
Solvency Due Diligence
Geron Corp's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Geron Corp's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GERN Price Targets Summary
Geron Corp
According to Wall Street analysts, the average 1-year price target for GERN is 5.185 USD with a low forecast of 4.545 USD and a high forecast of 6.3 USD.
Ownership
GERN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GERN Price
Geron Corp
Average Annual Return | 14.22% |
Standard Deviation of Annual Returns | 51.2% |
Max Drawdown | -53% |
Market Capitalization | 2.1B USD |
Shares Outstanding | 588 059 008 |
Percentage of Shares Shorted | 7.98% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 69 full-time employees. The firm operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).The Company has completed the evaluation of safety, tolerability, pharmacokinetics and pharmacodynamic effects of Imetelstat in its Phase I trials.
Contact
IPO
Employees
Officers
The intrinsic value of one GERN stock under the Base Case scenario is 10.708 USD.
Compared to the current market price of 3.805 USD, Geron Corp is Undervalued by 64%.